問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
林維祥
下載
2026-06-01 - 2030-06-30
Condition/Disease
Test Drug
Participate Sites14Sites
Recruiting14Sites
2025-03-01 - 2030-06-30
Participate Sites18Sites
Recruiting18Sites
2025-07-01 - 2030-12-31
Participate Sites23Sites
Recruiting23Sites
2023-04-13 - 2027-05-05
Participate Sites12Sites
Recruiting12Sites
2023-03-01 - 2027-02-28
Participate Sites17Sites
Recruiting17Sites
2024-07-30 - 2028-09-30
Not yet recruiting8Sites
Recruiting4Sites
2025-05-01 - 2029-06-30
Participate Sites8Sites
Recruiting8Sites
2025-09-30 - 2032-03-31
Participate Sites11Sites
Recruiting11Sites
2018-11-19 - 2022-12-01
Heart Failure With Preserved Ejection Fraction (HFpEF)
dapagliflozin film-coated tablets
Participate Sites15Sites
Recruiting13Sites
Division of Cardiovascular Diseases
2022-12-05 - 2024-09-30
Prevention of Ischemic Stroke 、Acute Non-cardioembolic Ischemic Stroke、 High-risk Transient Ischemic Attack
AsundexianPlacebo (for Asundexian)ApixabanPlacebo (for Apixaban)
Not yet recruiting2Sites
Recruiting20Sites
Terminated1Sites
全部
